ANIMATION

HuLuc 63

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.

Project


HuLuc 63


Client


PDL BioPharma

Both the quality of the final product and my experience working with XVIVO has reinforced my interest in a long-term collaboration with this team.

Alain Viel PhD, Senior Lecturer and Director of Undergraduate Research in Molecular and Cellular Biology, Harvard University